pubgnft|安进大涨近16%，减肥新药中期试验获积极数据

Gelonghui May 3| American pharmaceutical company Amgen (AMGNpubgnft.US) rose nearly 16% to $322.6 at the beginning of the sessionpubgnft, the largest one-day increase since 2009. In the news, Amgen's mid-term trial of a new weight-loss drug has received positive data. If the drug is approved, it will compete with Novo Nordisk's Wegovy and Lilly's Zepbound. Earlier, some media said that Amgen is trying a new weight-loss drug, whose mechanism of action is different from Novo Nordisk and Lilly products, which can prevent patients from gaining weight even if they stop taking the drug.